Stock indexes jumped at the Thursday's open, buoyed by optimism about progress on a COVID-19 vaccine candidates despite rising U.S. cases, while investors also grew bullish about better-than-expected results from Goldman Sachs Group, raising hope that quarterly results from the nation's financial system may be doing a slightly better job of contending with the recession caused by the viral outbreak. The Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +1.05% rose 384 points, or 1.4%, at 26,984, the S&P 500 index /zigman2/quotes/210599714/realtime SPX +1.40% gained 1% to 3,230, while the Nasdaq Composite Index /zigman2/quotes/210599714/realtime SPX +1.40% climbed 0.6% at 10,551.91. The rally in stocks in part has been boosted by news from Moderna Inc. /zigman2/quotes/205619834/composite MRNA +0.80% , which said its coronavirus vaccine candidate produced a "robust" immune-system response in a larger group of people and that the study would move to a further clinical trial in July. Markets also reacted positively to a separate report on developments for an Oxford University vaccine candidate backed by AstraZeneca PLC [s:UK: AZN] /zigman2/quotes/200304487/composite AZN +2.83% . Separately, Goldman Sachs /zigman2/quotes/209237603/composite GS +0.51% on Wednesday delivered results that beat expectations for revenue and earnings.